2012 - Porteurs du projet : Dr CREHANGE Gilles, Dr LADOIRE Sylvain - Partenaires : Pr MERLIN Jean-Louis, Dr MIRJOLET Céline, Dr SERVAGI-VERNAT Stéphanie

Etude prédictive des sarcomes développés en territoire irradié à partir de la base de données du GSF-GETO (SARI)

2011 - Porteur du projet : Pr MAINGON Philippe - Partenaire : Dr MIRJOLET Céline

Publications

Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer model.

Boustani J, Lecoester B, Baude J, Latour C, Limagne E, Ladjohoulou R, Morgand V, Froidurot L, Ghiringhelli F, Truc G, Adotévi O, Mirjolet C

Int J Radiat Biol. 2024 03 20;:1-10

Supramolecular Heterodimer Peptides Assembly for Nanoparticles Functionalization.

Mathieu C, Ghosh S, Draussin J, Gasser A, Jacquot G, Banerjee M, Gupta T, Schmutz M, Mirjolet C, Tillement O, Lux F, Klymchenko A, Donzeau M, Pivot X, Harlepp S, Detappe A

Adv Healthc Mater. 2024 03 5;:e2304250

Subcutaneous Administration of a Zwitterionic Chitosan-Based Hydrogel for Controlled Spatiotemporal Release of Monoclonal Antibodies.

Gréa T, Jacquot G, Durand A, Mathieu C, Gasser A, Zhu C, Banerjee M, Hucteau E, Mallard J, Lopez Navarro P, Popescu BV, Thomas E, Kryza D, Sidi-Boumedine J, Ferrauto G, Gianolio E, Fleith G, Combet J, Brun S, Erb S, Cianferani S, Charbonnière LJ, Fellmann L, Mirjolet C, David L, Tillement O, Lux F, Harlepp S, Pivot X, Detappe A

Adv Mater. 2023 12 17;:e2308738

The radio-induced immune response: ballistics is key.

Mirjolet C, Baude J

J Transl Med. 2023 11 15;21(1):813

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.

Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C

BMC Cancer. 2023 11 9;23(1):1080

Radiation-activated nanoparticles: Which combination to optimize radiosensitization?

Penninckx S, Martinive P, Mirjolet C

Cancer Radiother. 2023 08 4;:

Novel platform for subcutaneous tumor irradiation in mice.

Mirjolet C, Ladjohounlou R, Baude J, Bessières I

Methods Cell Biol. 2023 07 19;180:69-80

Radiation therapy-activated nanoparticle and immunotherapy: The next milestone in oncology?

Penninckx S, Thariat J, Mirjolet C

Int Rev Cell Mol Biol. 2023 04 21;378:157-200

Combining radiotherapy and NK cell-based therapies: The time has come.

Baude J, Limagne E, Ladjohounlou R, Mirjolet C

Int Rev Cell Mol Biol. 2023 03 24;378:31-60

Chemotherapy to potentiate the radiation-induced immune response.

Lecoester B, Wespiser M, Marguier A, Mirjolet C, Boustani J, Adotévi O

Int Rev Cell Mol Biol. 2023 02 11;376:143-173

Dual impact of radiation therapy on tumor-targeting immune responses.

Mirjolet C, Baude J, Galluzzi L

Int Rev Cell Mol Biol. 2023 ;378:xiii-xxiv

Challenges in glioblastoma research: focus on the tumor microenvironment.

Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, Clavreul A, Constantin B, Coronas V, Daubon T, Dontenwill M, Ducray F, Enz-Werle N, Figarella-Branger D, Fournier I, Frenel JS, Gabut M, Galli T, Gavard J, Huberfeld G, Hugnot JP, Idbaih A, Junier MP, Mathivet T, Menei P, Meyronet D, Mirjolet C, Morin F, Mosser J, Moyal EC, Rousseau V, Salzet M, Sanson M, Seano G, Tabouret E, Tchoghandjian A, Turchi L, Vallette FM, Vats S, Verreault M, Virolle T

Trends Cancer. 2022 11 15;:

Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study.

Deneuve S, Bastogne T, Duclos M, Mirjolet C, Bois P, Bachmann P, Nokovitch L, Roux PE, Girodet D, Poupart M, Zrounba P, Claude L, Ferella L, Iacovelli NA, Foray N, Rancati T, Pereira S

Tumori. 2022 05 16;:3008916221078061

Treatment related factors associated with the risk of breast radio-induced-sarcoma.

Mirjolet C, Diallo I, Bertaut A, Veres C, Sargos P, Helfre S, Sunyach MP, Truc G, Le Pechoux C, Paumier A, Ducassou A, Jolnerovski M, Thariat J, Lapeyre M, Cordoba A, Mahé MA, Maingon P

Radiother Oncol. 2022 Apr 8;:

About the Influence of PEG Spacers on the Cytotoxicity of Titanate Nanotubes-Docetaxel Nanohybrids against a Prostate Cancer Cell Line.

Loiseau A, Boudon J, Mirjolet C, Morgand V, Millot N

Nanomaterials (Basel). 2021 Oct 15;11(10):

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies.

Boustani J, Lecoester B, Baude J, Latour C, Adotevi O, Mirjolet C, Truc G

Cancers (Basel). 2021 Sep 29;13(19):

[Abscopal effect: Myth or reality?]

Mirjolet C, Truc G

Cancer Radiother. 2021 Aug 27;:

Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.

Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, Marguier A, Tochet F, Dosset M, Boustani J, Ravel P, Boidot R, Spehner L, Haicheur-Adjouri N, Marliot F, Pallandre JR, Bonnefoy F, Scripcariu V, Van den Eynde M, Cornillot E, Mirjolet C, Pages F, Adotevi O

J Immunother Cancer. 2021 Jul;9(7):

Impact of proton therapy on antitumor immune response.

Mirjolet C, Nicol A, Limagne E, Mura C, Richard C, Morgand V, Rousseau M, Boidot R, Ghiringhelli F, Noel G, Burckel H

Sci Rep. 2021 Jun 29;11(1):13444

Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood.

Boustani J, Joseph ELM, Martin E, Benhmida S, Lecoester B, Tochet F, Mirjolet C, Chevalier C, Thibouw D, Vulquin N, Servagi S, Sun X, Adotévi O

BMC Immunol. 2021 Jun 18;22(1):38

Proof of Concept of a Binary Blood Assay for Predicting Radiosensitivity.

Deneuve S, Mirjolet C, Bastogne T, Duclos M, Retif P, Zrounba P, Roux PE, Poupart M, Vogin G, Foray N, Pereira S

Cancers (Basel). 2021 May 19;13(10):

Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer.

Boustani J, Derangère V, Bertaut A, Adotevi O, Morgand V, Charon-Barra C, Ghiringhelli F, Mirjolet C

Cells. 2020 Sep 10;9(9):

and impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response.

Laurent PA, Kownacka A, Boidot R, Richard C, Limagne E, Morgand V, Froidurot L, Bonin C, Aubignac L, Ghiringhelli F, Créhange G, Mirjolet C

Clin Transl Radiat Oncol. 2020 Sep;24:116-122

Titanate Nanotubes Engineered with Gold Nanoparticles and Docetaxel to Enhance Radiotherapy on Xenografted Prostate Tumors.

Loiseau A, Boudon J, Oudot A, Moreau M, Boidot R, Chassagnon R, Saïd NM, Roux S, Mirjolet C, Millot N

Cancers (Basel). 2019 Dec 6;11(12):

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.

Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet JD, Crehange G, Ghiringhelli F, Mirjolet C

J Immunother Cancer. 2019 Jun 25;7(1):160

The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response.

Boustani J, Grapin M, Laurent PA, Apetoh L, Mirjolet C

Cancers (Basel). 2019 Jun 20;11(6):

RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study.

Mirjolet C, Merlin JL, Truc G, Noël G, Thariat J, Domont J, Sargos P, Renard-Oldrini S, Ray-Coquard I, Liem X, Chevreau C, Lagrange JL, Mahé MA, Collin F, Bonnetain F, Bertaut A, Maingon P

EBioMedicine. 2019 Feb 28;:

Polydopamine Modified Superparamagnetic Iron Oxide Nanoparticles as Multifunctional Nanocarrier for Targeted Prostate Cancer Treatment.

Singh N, Sallem F, Mirjolet C, Nury T, Sahoo SK, Millot N, Kumar R

Nanomaterials (Basel). 2019 Jan 22;9(2):

HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells.

Causse SZ, Marcion G, Chanteloup G, Uyanik B, Boudesco C, Grigorash BB, Douhard R, Dias AMM, Dumetier B, Dondaine L, Gozzi GJ, Moussay E, Paggetti J, Mirjolet C, de Thonel A, Dubrez L, Demidov ON, Gobbo J, Garrido C

Oncogene. 2018 Dec 12;:

Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy.

Thibouw D, Truc G, Bertaut A, Chevalier C, Aubignac L, Mirjolet C

J. Neurooncol.. 2018 Apr;137(2):429-438

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study.

Mirjolet C, Charon-Barra C, Ladoire S, Arbez-Gindre F, Bertaut A, Ghiringhelli F, Leroux A, Peiffert D, Borg C, Bosset JF, Créhange G

Oncoimmunology. 2018 ;7(3):e1396402

NOX2-dependent ATM kinase activation dictates pro-inflammatory macrophage phenotype and improves effectiveness to radiation therapy.

Wu Q, Allouch A, Paoletti A, Leteur C, Mirjolet C, Martins I, Voisin L, Law F, Dakhli H, Mintet E, Thoreau M, Muradova Z, Gauthier M, Caron O, Milliat F, Ojcius DM, Rosselli F, Solary E, Modjtahedi N, Deutsch E, Perfettini JL

Cell Death Differ.. 2017 Jun;:

Taxane-Grafted Metal-Oxide Nanoparticles as a New Theranostic Tool against Cancer: The Promising Example of Docetaxel-Functionalized Titanate Nanotubes on Prostate Tumors.

Loiseau A, Boudon J, Mirjolet C, Créhange G, Millot N

Adv Healthc Mater. 2017 May;:

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model.

Mirjolet C, Boudon J, Loiseau A, Chevrier S, Boidot R, Oudot A, Collin B, Martin E, Joy PA, Millot N, Créhange G

Int J Nanomedicine. 2017 ;12:6357-6364

Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer.

Mirjolet C, Walker PM, Gauthier M, Dalban C, Naudy S, Mazoyer F, Martin E, Maingon P, Créhange G

Radiat Oncol. 2016 Nov;11(1):145

[Sarcoma developed in irradiated area: Preliminary results of the SARI trial].

Maingon P, Mirjolet C, Diallo I, Veres C, Collin F, Italiano A, Chibon F, Merlin JL, Coindre JM

Cancer Radiother. 2016 Oct;20(6-7):690-3

Correlation between radio-induced lymphocyte apoptosis measurements obtained from two French centres.

Mirjolet C, Merlin JL, Dalban C, Maingon P, Azria D

Cancer Radiother. 2016 Jul;20(5):391-4

A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma.

Truc G, Bernier V, Mirjolet C, Dalban C, Mazoyer F, Bonnetain F, Blanchard N, Lagneau É, Maingon P, Noël G

Cancer Radiother. 2016 May;20(3):193-8

The role of telomeres in predicting individual radiosensitivity of patients with cancer in the era of personalized radiotherapy.

Mirjolet C, Boidot R, Saliques S, Ghiringhelli F, Maingon P, Crehange G

Cancer Treat Rev. 2015 Apr;41(4):354-60

[Reirradiations of head and neck cancers: state of the concept and ways of development].

Soltys B, Wiazzane N, Mirjolet C, Dalban C, Serre AA, Zanetta S, Thiebaut S, Crehange G, Maingon P

Cancer Radiother. 2013 Oct;17(5-6):508-12

[The role of whole brain radiotherapy with hippocampal-sparing].

Truc G, Martin E, Mirjolet C, Chamois J, Petitfils A, Crehange G

Cancer Radiother. 2013 Oct;17(5-6):419-23

Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy.

Vegran F, Mary R, Gibeaud A, Mirjolet C, Collin B, Oudot A, Charon-Barra C, Arnould L, Lizard-Nacol S, Boidot R

Cancer Res. 2013 Sep 1;73(17):5391-401

The radiosensitization effect of titanate nanotubes as a new tool in radiation therapy for glioblastoma: a proof-of-concept.

Mirjolet C, Papa AL, Crehange G, Raguin O, Seignez C, Paul C, Truc G, Maingon P, Millot N

Radiother Oncol. 2013 Jul;108(1):136-42

Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer.

Crehange G, Mirjolet C, Gauthier M, Martin E, Truc G, Peignaux-Casasnovas K, Azelie C, Bonnetain F, Naudy S, Maingon P

Radiother Oncol. 2012 May;103(2):244-6

Exclusive image-guided IMRT versus radical prostatectomy followed by postoperative IMRT for localized prostate cancer: A matched-pair analysis based on risk groups.

Azelie C, Gauthier M, Mirjolet-Didelot C, Cormier L, Martin E, Peignaux-Casasnovas K, Truc G, Maingon P, Crehange G

J. Clin. Oncol.. 2012 Feb;30(5_suppl):135

MR spectroscopy compared with DW-MRI and DCE-MRI at 3-tesla for the noninvasive prediction of short-term radiation response for patients with localized prostate cancer.

Crehange G, Maingon P, Gauthier M, Cochet A, Martin E, Mirjolet-Didelot C, Cormier L, Bonnetain F, Vignon N, Brunotte F, Walker PM

J. Clin. Oncol.. 2012 Feb;30(5_suppl):122

Use of the slope of the DVH curve for predicting late rectal toxicity in IMRT for patients with localized prostate cancer.

Crehange G, Walker PM, Gauthier M, Mirjolet-Didelot C, Petitfils A, Martin E, Chamois J, Khoury C, Maingon P

J. Clin. Oncol.. 2012 Feb;30(5_suppl):230

Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups.

Azelie C, Gauthier M, Mirjolet C, Cormier L, Martin E, Peignaux-Casasnovas K, Truc G, Chamois J, Maingon P, Crehange G

Radiat Oncol. 2012 Sep 17;7:158

Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year.

Crehange G, Maingon P, Gauthier M, Parfait S, Cochet A, Mirjolet C, Bonnetain F, Cormier L, Brunotte F, Walker P

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e407-13

Tumor volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential clinical implications in the context of radiation oncology.

Crehange G, Parfait S, Liegard M, Maingon P, Ben Salem D, Cochet A, Funes de la Vega M, Cormier L, Bonnetain F, Mirjolet C, Brunotte F, Walker PM

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1087-94

Interaction of heat-shock protein 90 beta isoform (HSP90 beta) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation.

Didelot C, Lanneau D, Brunet M, Bouchot A, Cartier J, Jacquel A, Ducoroy P, Cathelin S, Decologne N, Chiosis G, Dubrez-Daloz L, Solary E, Garrido C

Cell Death Differ. 2008 May;15(5):859-66

[Mitochondria HSP90: the target to inactivate in cancer therapy?]

Didelot C, Garrido C

Med Sci (Paris). 2008 Apr;24(4):363-4.

Interaction of heat-shock protein 90beta isoform (HSP90beta) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation.

Didelot C, Lanneau D, Brunet M, Bouchot A, Cartier J, Jacquel A, Ducoroy P, Cathelin S, Decologne N, Chiosis G, Dubrez-Daloz L, Solary E, Garrido C

Cell Death Differ. 2008 Feb 1

Oncoprotein expression of E6 and E7 does not prevent 5-fluorouracil (5FU) mediated G1/S arrest and apoptosis in 5FU resistant carcinoma cell lines.

Didelot C, Mirjolet JF, Barberi-Heyob M, Ramacci C, Teiten MH, Merlin JL

Int. J. Oncol.. 2003 Jul;23(1):81-7

Radiation could induce p53-independent and cell cycle--unrelated apoptosis in 5-fluorouracil radiosensitized head and neck carcinoma cells.

Didelot C, Mirjolet JF, Barberi-Heyob M, Ramacci C, Merlin JL

Can. J. Physiol. Pharmacol.. 2002 Jul;80(7):638-43